MOTS-c Legal Status, FDA 503A Category, and Compounding Access

In plain English

The headline first: the MOTS-c legal status is moving, and 2026 could be a turning point. MOTS-c is named by name on the published agenda of an FDA advisory-committee meeting set for July 23-24, 2026, where it will be considered for a list that governs pharmacy compounding. That is real momentum. But it is a scheduled discussion, not a decision — and as of today the facts are unchanged: MOTS-c is not an FDA-approved drug, it is sold only for laboratory research, and it has no approved human use. This page explains the rules behind that, in general terms. It is information, not legal or medical advice, and not an offer to sell anything.

Current status: a research peptide, not an approved drug

Stated plainly and in the present tense: MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication [F1]. No approved human indication, formulation, or dosing exists, and the molecule is distributed only as a research chemical for laboratory use ^[4].

Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) [F1]. MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation — and being under evaluation is not the same as being on the bulks list or approved for compounding [F3].

One accuracy note this digest holds firmly: the audited regulatory reference assigns detailed 503A category placements only to certain other peptides. It does not assign MOTS-c a 503A category, so this page does not state or imply one. MOTS-c's present-tense status is exactly as above — a research peptide, not FDA-approved, scheduled for PCAC evaluation [F1][F3].

The momentum: MOTS-c on the July 2026 PCAC agenda

Here is the forward-looking fact, stated carefully. MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [F3]. It is evaluated there in both free-base and acetate forms, and the same agenda also lists BPC-157, TB-500, and KPV [F3].

That placement on the agenda is genuine movement — it means MOTS-c is actively in front of FDA's advisory committee, and the compounding landscape for these peptides may expand in 2026. But the limits are just as real. A PCAC meeting is a scheduled evaluation and discussion only [F3]. It is not a listing decision, not a reclassification, and not a change in MOTS-c's current status. A PCAC discussion is advisory; inclusion on a final 503A bulks list is decided separately by FDA rulemaking [F1]. No outcome of the July 2026 meeting should be assumed, and none is asserted here.

This digest also does not repeat the unconfirmed claims circulating elsewhere — for example, that a batch of peptides was "moved back" toward an earlier category in early 2026, or "removed" from a category in April 2026. The audited reference lists those as explicitly unconfirmed, pending matters rather than completed FDA actions, so they are excluded here [F1].

The 503A and 503B framework, in general terms

Two sections of the Act govern drug compounding [F1]. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection.

The ingredient question is the gate. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise the substance must be nominated and evaluated by FDA [F1]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding [F1]. Because MOTS-c is not FDA-approved and is currently a substance under PCAC evaluation rather than one on the bulks list, that eligibility question is unresolved while its status stands [F1][F3].

How legally compounded peptide access works

In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [F2]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [F2].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [F2]. The ingredient-eligibility caveat always applies: an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [F2].

This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing or administration instructions, and describes no way to obtain any substance outside the lawful framework. It is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance [F2].